Impact of hemochromatosis gene mutations on cardiac status in doxorubicin-treated survivors of childhood high-risk leukemia

Cancer

Volumn 119, Issue 19, 2013, Pages 3555-3562

  Lipshultz, Steven E ^a,b   Lipsitz, Stuart R ^c   Kutok, Jeffery L ^c   Miller, Tracie L ^a   Colan, Steven D ^d   Neuberg, Donna S ^e   Stevenson, Kristen E ^e   Fleming, Mark D ^d   Sallan, Stephen E ^d   Franco, Vivian I ^a   Henkel, Jacqueline M ^a   Asselin, Barbara L ^f   Athale, Uma H ^g   Clavell, Luis A ^h   Michon, Bruno ⁱ   Laverdiere, Caroline ^j   Larsen, Eric ^k   Kelly, Kara M ^l   Silverman, Lewis B ^d  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MIAMI   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d BOSTON CHILDREN S HOSPITAL   (United States)

^e DANA FARBER CANCER INSTITUTE   (United States)

^f UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^g MCMASTER UNIVERSITY   (Canada)

^h San Jorge Children's Hospital   (Puerto Rico)

ⁱ LAVAL UNIVERSITY   (Canada)

^j UNIVERSITY OF MONTREAL   (Canada)

^k Maine Children Cancer Program   (United States)

^l Och Spine at New York Presbyterian Hospitals   (United States)

more..

Author keywords

cardiotoxicity; doxorubicin; hemochromatosis; leukemia; pediatrics

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; DOXORUBICIN; RAZOXANE; TROPONIN T; TUMOR MARKER;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; CANCER RISK; CANCER SURVIVOR; CARDIOMYOPATHY; CHILD; CHILDHOOD LEUKEMIA; CONTROLLED STUDY; DNA DETERMINATION; ECHOCARDIOGRAPHY; FEMALE; GENE FREQUENCY; GENETIC VARIABILITY; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART LEFT VENTRICLE ENDSYSTOLIC VOLUME; HEART LEFT VENTRICLE FUNCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE INJURY; HEMOCHROMATOSIS GENE; HETEROZYGOSITY; HIGH RISK PATIENT; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; RISK FACTOR; SCORING SYSTEM; TUMOR GENE; Z SCORE;

CARDIOTOXICITY; DOXORUBICIN; HEMOCHROMATOSIS; LEUKEMIA; PEDIATRICS;

ADOLESCENT; CARDIOTOXINS; CHILD; CHILD, PRESCHOOL; DISEASE-FREE SURVIVAL; DOXORUBICIN; ECHOCARDIOGRAPHY; FEMALE; GENETIC COUNSELING; GENOTYPE; HEART DISEASES; HEMOCHROMATOSIS; HUMANS; MALE; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; SURVIVORS;

EID: 84884908105     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.28256     Document Type: Article

References (40)

1. Siegel R, Naishadham D, Jemal A,. Cancer statistics, 2013. CA Cancer J Clin. 2013; 63: 11-30.
2. Mariotto AB, Rowland JH, Yabroff KR, et al. Long-term survivors of childhood cancers in the United States. Cancer Epidemiol Biomarkers Prev. 2009; 18: 1033-1040.
3. Krischer JP, Epstein S, Cuthbertson DD, et al. Clinical cardiotoxicity following anthracycline treatment for childhood cancer: the Pediatric Oncology Group experience. J Clin Oncol. 1997; 15: 1544-1552.
4. Lipshultz SE, Lipsitz SR, Sallan SE, et al. Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia. J Clin Oncol. 2005; 23: 2629-2636.
5. Lipshultz SE, Colan SD, Gelber RD, et al. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N Engl J Med. 1991; 324: 808-815.
6. Lipshultz SE, Lipsitz SR, Mone SM, et al. Female sex and drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer. N Engl J Med. 1995; 332: 1738-1743.
7. Tomizawa D, Tawa A, Watanabe T, et al. Excess reduction of anthracyclines results in inferior event-free survival in core binding factor acute myeloid leukemia in children: a report from the Japanese Pediatric Leukemia/Lymphoma Study Group (JPLSG) [abstract]. Blood. 2012; 120:Abstract 409.
8. Link G, Tirosh R, Pinson A, Hershko C,. Role of iron in the potentiation of anthracycline cardiotoxicity: identification of heart cell mitochondria as a major site of iron-anthracycline interaction. J Lab Clin Med. 1996; 127: 272-278.
9. Wallace KB,. Doxorubicin-induced cardiac mitochondrionopathy. Pharmacol Toxicol. 2003; 93: 105-115.
10. Buss JL, Hasinoff BB,. The one-ring open hydrolysis product intermediates of the cardioprotective agent ICRF-187 (dexrazoxane) displace iron from iron-anthracycline complexes. Agents Actions. 1993; 40: 86-95.
11. Lipshultz SE, Rifai N, Dalton VM, et al. The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia. N Engl J Med. 2004; 351: 145-153.
12. Hershko C, Link G, Tzahor M, et al. Anthracycline toxicity is potentiated by iron and inhibited by deferoxamine: studies in rat heart cells in culture. J Lab Clin Med. 1993; 122: 245-251.
13. Neghina AM, Anghel A,. Hemochromatosis genotypes and risk of iron overload-a meta-analysis. Ann Epidemiol. 2011; 21: 1-14.
14. Erhardt A, Mellenthin C, Perings C, et al. HFE mutations in idiopathic dilated cardiomyopathy. Med Klin (Munich). 2006; 101 (suppl 1): 135-138.
15. Hannuksela J, Leppilampi M, Peuhkurinen K, et al. Hereditary hemochromatosis gene (HFE) mutations C282Y, H63D, and S65C in patients with idiopathic dilated cardiomyopathy. Eur J Heart Fail. 2005; 7: 103-108.
16. Balagtas JM, Dahl GV,. Therapeutic complications in a patient with high-risk acute lymphoblastic leukemia and undiagnosed hereditary hemochromatosis. Pediatr Blood Cancer. 2012; 58: 101-103.
17. Goland S, Beilinson N, Kaftouri A, et al. Hemochromatosis mutations are not linked to dilated cardiomyopathy in Israeli patients. Eur J Heart Fail. 2004; 6: 547-550.
18. Visscher H, Ross CJD, Rassekh SR, et al. Pharmacogenomic prediction of anthracycline-induced cardiotoxicity in children. J Clin Oncol. 2012; 30: 1422-1428.
19. Blanco JG, Sun CL, Landier W, et al. Anthracycline-related cardiomyopathy after childhood cancer: role of polymorphisms in carbonyl reductase genes-a report from the Children's Oncology Group. J Clin Oncol. 2012; 30: 1415-1421.
20. Silverman LB, Stevenson KE, O'Brien JE, et al. Long-term results of Dana-Farber Cancer Institute ALL Consortium protocols for children with newly diagnosed acute lymphoblastic leukemia (1985-2000). Leukemia. 2010; 24: 320-334.
21. 2 HIV study. Circulation. 2001; 104: 310-316.
22. Lopez L, Colan SD, Frommelt PC, et al. Recommendations for quantification methods during the performance of a pediatric echocardiogram: a report from the Pediatric Measurements Writing Group of the American Society of Echocardiography Pediatric and Congenital Heart Disease Council. J Am Soc Echocardiogr. 2010; 23: 465-495; quiz 576-577.
23. Colan SD, Parness IA, Spevak PJ, Sanders SP,. Developmental modulation of myocardial mechanics: age- and growth-related alterations in afterload and contractility. J Am Coll Cardiol. 1992; 19: 619-629.
24. Sluysmans T, Colan SD,. Theoretical and empirical derivation of cardiovascular allometric relationships in children. J Appl Physiol. 2005; 99: 445-457.
25. Steinberg KK, Cogswell ME, Chang JC, et al. Prevalence of C282Y and H63D mutations in the hemochromatosis (HFE) gene in the United States. JAMA. 2001; 285: 2216-2222.
26. Miranda CJ, Makui H, Soares RJ, et al. Hfe deficiency increases susceptibility to cardiotoxicity and exacerbates changes in iron metabolism induced by doxorubicin. Blood. 2003; 102: 2574-2580.
27. van der Pal HJ, van Dalen EC, van Delden E, et al. High risk of symptomatic cardiac events in childhood cancer survivors. J Clin Oncol. 2012; 30: 1429-1437.
28. Armenian SH, Ding Y, Mills G, et al. Genetic susceptibility to anthracycline-related congestive heart failure (CHF) in survivors of hematopoietic cell transplantation (HCT) [abstract]. Blood. 2012; 120:Abstract 589.
29. Cascales A, Sanchez-Vega B, Navarro N, et al. Clinical and genetic determinants of anthracycline-induced cardiac iron accumulation. Int J Cardiol. 2012; 154: 282-286.
30. Nahon P, Sutton A, Pessayre D, et al. Do genetic variations in antioxidant enzymes influence the course of hereditary hemochromatosis? Antioxid Redox Signal. 2011; 15: 31-38.
31. Livesey KJ, Wimhurst VL, Carter K, et al. The 16189 variant of mitochondrial DNA occurs more frequently in C282Y homozygotes with haemochromatosis than those without iron loading. J Med Genet. 2004; 41: 6-10.
32. Lipshultz SE, Scully RE, Lipsitz SR, et al. Assessment of dexrazoxane as a long-term cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukemia: a prospective, randomized, multicentre trial. Lancet Oncol. 2010; 11: 950-961.
33. Vrooman LM, Neuberg DS, Stevenson KE, et al. The low incidence of secondary acute myelogenous leukaemia in children and adolescents treated with dexrazoxane for acute lymphoblastic leukaemia: a report from the Dana-Farber Cancer Institute ALL Consortium. Eur J Cancer. 2011; 47: 1373-1379.
34. Barry EV, Vrooman LM, Dahlberg SE, et al. Absence of secondary malignant neoplasms in children with high-risk acute lymphoblastic leukemia treated with dexrazoxane. J Clin Oncol. 2008; 26: 1106-1111.
35. Lipshultz SE, Miller TL, Scully RE, et al. Changes in cardiac biomarkers during doxorubicin treatment of pediatric patients with high-risk acute lymphoblastic leukemia: associations with long-term echocardiographic outcomes. J Clin Oncol. 2012; 30: 1042-1049.
36. Asselin B, Devidas M, Zhou T, et al. Cardioprotection and safety of dexrazoxane (DRZ) in children treated for newly diagnosed T-cell acute lymphoblastic leukemia (T-ALL) or advanced stage lymphoblastic leukemia (T-LL) [abstract]. J Clin Oncol. 2012; 30 (suppl): Abstract 9504.
37. Kopp LM, Bernstein ML, Schwartz CL, et al. The effects of dexrazoxane on cardiac status and second malignant neoplasms (SMN) in doxorubicin-treated patients with osteosarcoma (OS) [abstract]. J Clin Oncol. 2012; 30 (suppl):Abstract 9503.
38. Ebb D, Meyers P, Grier H, et al. Phase II trial of trastuzumab in combination with cytotoxic chemotherapy for treatment of metastatic osteosarcoma with human epidermal growth factor receptor 2 overexpression: a report from the Children's Oncology Group. J Clin Oncol. 2012; 30: 2545-2551.
39. Nadakkavukaran IM, Gan EK, Olynyk JK,. Screening for hereditary haemochromatosis. Pathology. 2012; 44: 148-152.
40. Lutz K, von Komorowski G, Durken M, et al. Myocardial iron overload in transfusion-dependent pediatric patients with acute leukemia. Pediatr Blood Cancer. 2008; 51: 691-693.